Cargando…
Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer
BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) is a unique subtype of this disease. Few studies focus on the feasibility of trastuzumab as maintenance or palliative therapy for patients with HER2-positive advanced GC. PATIENTS AND METHODS: We retrospectively...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157990/ https://www.ncbi.nlm.nih.gov/pubmed/30275713 http://dx.doi.org/10.2147/OTT.S174138 |
_version_ | 1783358359353688064 |
---|---|
author | Fu, Xiaomin Zhang, Yong Yang, Jing Qi, Yalong Ming, Yue Sun, Miaomiao Shang, Yiman Yang, Yonghao Zhu, Xiaoyan Gao, Quanli |
author_facet | Fu, Xiaomin Zhang, Yong Yang, Jing Qi, Yalong Ming, Yue Sun, Miaomiao Shang, Yiman Yang, Yonghao Zhu, Xiaoyan Gao, Quanli |
author_sort | Fu, Xiaomin |
collection | PubMed |
description | BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) is a unique subtype of this disease. Few studies focus on the feasibility of trastuzumab as maintenance or palliative therapy for patients with HER2-positive advanced GC. PATIENTS AND METHODS: We retrospectively analyzed the data of 11 patients, evaluated the efficacy and safety of trastuzumab, and attempted to investigate the prognostic factors for trastuzumab treatment. Among the 11 patients, one achieved partial response (PR), six achieved stable disease (SD), and four were evaluated as progressive disease (PD). RESULTS: The overall response rate (ORR) was 9.10%, and the disease control rate (DCR) was 63.64%. The median overall survival (OS) was 6.10 months, and the median progression-free survival (PFS) was 6.10 months. A significant association was found between trastuzumab treatment cycles and efficacy (P=0.027), cycles and PFS (P=0.001), and cycles and OS (P=0.005). Among the five patients who accepted more than five cycles of trastuzumab, the median OS and median PFS achieved 23.83 months and 14.67 months, respectively. Moreover, we have found the correlation between tumor marker changes and efficacy (P=0.002) and HER2 status and PFS (P=0.027). No association was found between HER2 status and OS (P=0.597). CONCLUSION: The most common adverse events were left ventricular ejection fraction (LVEF) reduction, fatigue, and anorexia. LVEF reduction was found in seven of 11 patients, but the absolute decline in the LVEF was within 10% from the baseline. The results of this study suggest that trastuzumab is a feasible option as maintenance or palliative therapy for patients with HER2-positive metastatic GC. |
format | Online Article Text |
id | pubmed-6157990 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-61579902018-10-01 Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer Fu, Xiaomin Zhang, Yong Yang, Jing Qi, Yalong Ming, Yue Sun, Miaomiao Shang, Yiman Yang, Yonghao Zhu, Xiaoyan Gao, Quanli Onco Targets Ther Original Research BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) is a unique subtype of this disease. Few studies focus on the feasibility of trastuzumab as maintenance or palliative therapy for patients with HER2-positive advanced GC. PATIENTS AND METHODS: We retrospectively analyzed the data of 11 patients, evaluated the efficacy and safety of trastuzumab, and attempted to investigate the prognostic factors for trastuzumab treatment. Among the 11 patients, one achieved partial response (PR), six achieved stable disease (SD), and four were evaluated as progressive disease (PD). RESULTS: The overall response rate (ORR) was 9.10%, and the disease control rate (DCR) was 63.64%. The median overall survival (OS) was 6.10 months, and the median progression-free survival (PFS) was 6.10 months. A significant association was found between trastuzumab treatment cycles and efficacy (P=0.027), cycles and PFS (P=0.001), and cycles and OS (P=0.005). Among the five patients who accepted more than five cycles of trastuzumab, the median OS and median PFS achieved 23.83 months and 14.67 months, respectively. Moreover, we have found the correlation between tumor marker changes and efficacy (P=0.002) and HER2 status and PFS (P=0.027). No association was found between HER2 status and OS (P=0.597). CONCLUSION: The most common adverse events were left ventricular ejection fraction (LVEF) reduction, fatigue, and anorexia. LVEF reduction was found in seven of 11 patients, but the absolute decline in the LVEF was within 10% from the baseline. The results of this study suggest that trastuzumab is a feasible option as maintenance or palliative therapy for patients with HER2-positive metastatic GC. Dove Medical Press 2018-09-20 /pmc/articles/PMC6157990/ /pubmed/30275713 http://dx.doi.org/10.2147/OTT.S174138 Text en © 2018 Fu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Fu, Xiaomin Zhang, Yong Yang, Jing Qi, Yalong Ming, Yue Sun, Miaomiao Shang, Yiman Yang, Yonghao Zhu, Xiaoyan Gao, Quanli Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer |
title | Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer |
title_full | Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer |
title_fullStr | Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer |
title_full_unstemmed | Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer |
title_short | Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer |
title_sort | efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced her2-positive gastric cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157990/ https://www.ncbi.nlm.nih.gov/pubmed/30275713 http://dx.doi.org/10.2147/OTT.S174138 |
work_keys_str_mv | AT fuxiaomin efficacyandsafetyoftrastuzumabasmaintenanceorpalliativetherapyinadvancedher2positivegastriccancer AT zhangyong efficacyandsafetyoftrastuzumabasmaintenanceorpalliativetherapyinadvancedher2positivegastriccancer AT yangjing efficacyandsafetyoftrastuzumabasmaintenanceorpalliativetherapyinadvancedher2positivegastriccancer AT qiyalong efficacyandsafetyoftrastuzumabasmaintenanceorpalliativetherapyinadvancedher2positivegastriccancer AT mingyue efficacyandsafetyoftrastuzumabasmaintenanceorpalliativetherapyinadvancedher2positivegastriccancer AT sunmiaomiao efficacyandsafetyoftrastuzumabasmaintenanceorpalliativetherapyinadvancedher2positivegastriccancer AT shangyiman efficacyandsafetyoftrastuzumabasmaintenanceorpalliativetherapyinadvancedher2positivegastriccancer AT yangyonghao efficacyandsafetyoftrastuzumabasmaintenanceorpalliativetherapyinadvancedher2positivegastriccancer AT zhuxiaoyan efficacyandsafetyoftrastuzumabasmaintenanceorpalliativetherapyinadvancedher2positivegastriccancer AT gaoquanli efficacyandsafetyoftrastuzumabasmaintenanceorpalliativetherapyinadvancedher2positivegastriccancer |